Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

In the third quarter, Tremfya generated global sales of $1.01 billion, 13% year over year. The European Medicines Agency is ...

Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study of its dual-acting IL-23 inhibitor Tremfya ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...

Johnson & Johnson recently rolled out a TV ad that takes aim at a major disparity in dermatology: the fact that people of ...

The FDA approved Tremfya in September 2024 for moderately to severely active ulcerative colitis. The application for moderately to severely active Crohn's disease is currently under FDA review.

Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...

At week 16, an IGA score of 0 or 1 was met for guselkumab vs placebo in scalp (75.0% vs 14.5%), face (87.8% vs 28.6%), intertriginous (86.5% vs 28.8%) and genital (78.0% vs 37.5%). A phase 3b ...

(RTTNews) - Johnson & Johnson (JNJ) Monday announced positive results from Phase 3 GRAVITI study of Tremfya as both induction and maintenance therapy in Crohn's disease, a type of inflammatory ...

Tremfya (guselkumab) is a prescription drug that’s used to treat certain autoimmune conditions, including plaque psoriasis. Tremfya can cause side effects that range from mild to serious.

First-of-its-kind Phase 3b study shows TREMFYA® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement ...